Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Chris Boylan who wrote (9030)	3/9/1999 5:55:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

"I can't remember seeing anything about the morbidity results from the earlier phase I/II so I don't know if that's realistic or not in this phase III." The amputations are frequent in the survivors if decrease could be a claim for approval as significant decrease in morbidity. This was proven in phase II, when compared to historical groups. Then one is at the same crossroads, wait for the phase III confirmation. I will not like this from a Market point of view (it will go to $0.5 anyway). for the patients any good result is good. And if bpi has a marginal improvement in survivability it could also increase the amputations (the one who will die has more chances for lost of limbs),and will complicate the matter anyway, or $0.5 as per the Street. Hope for decrease mortality, and statistical significance. Xoma will make it or brake it. No room for the faint here, Unless one is like Robert S and justifiably wait for the FDA approval